Neuroscience
The Associated Press reported this evening about today's FDA meeting (see yesterday's post: Forthcoming Meeting...):
FDA Panel Urges More Studies of Stroke Med
By THE ASSOCIATED PRESS (copyright)
Filed at 8:51 p.m. ET
WILMINGTON, Del. (AP) -- A U.S. advisory panel on Friday recommended against approving AstraZeneca's new stroke prevention medication, Exanta, citing concerns about the drug's effect on the liver.
An advisory panel of physicians, meeting in Bethesda, Md., advised the Food and Drug Administration that more long-term studies are needed to assess the drug's safety, The (Wilmington) News Journal reported.
The FDA usually follows the recommendations of its advisory panels. The agency is expected to announce a decision on Exanta next month.
At the hearing, AstraZeneca made its case for Exanta's approval to the panel. Hamish Cameron, a company vice president, told the panel that Exanta represents a "real advance'' in the prevention of strokes.
But Ruyi He, an FDA official, told the panel that clinical testing of Exanta raised concerns that the drug could cause severe liver damage. He also raised concerns that patients taking Exanta may have a higher risk of heart attack.
AstraZeneca executives have portrayed Exanta as an alternative to the widely prescribed drug warfarin. Both drugs are supposed to reduce the risk of stroke by preventing blood clots.
AstraZeneca closed down 66 cents, to $43.73, on the New York Stock Exchange. The panel's recommendations were announced after the close of trading.
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...
- Potiga (ezogabine)
From FierceBiotech FDA panel backs new epilepsy drug from GSK, Valeant August 12, 2010 — 7:41am ET By John Carroll "GlaxoSmithKline and Valeant got a solid endorsement for their new epilepsy drug Potiga (ezogabine) from the FDA's panel of experts,...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...
- Methylphenidate Transdermal Patch (daytrana), Adhd, & The Fda: Thursday And Friday
THURSDAY: From The Washington Post website:Problem Found With Potential ADHD Patch The Associated Press Thursday, December 1, 2005; 3:01 PM WASHINGTON -- A patch developed to treat attention deficit hyperactivity disorder in children received a negative...
- Business World: Astrazeneca, Renovis - Cerovive (nxy-059) In Stroke Treatment
From TheStreet.com:AstraZeneca's Results Boost Tiny Renovis By Robert Steyer TheStreet.com Staff Reporter 5/4/2005 1:03 PM EDT AstraZeneca (AZN :NYSE - commentary -research ) reported mixed results for a late-stage clinical trial of an experimental...
Neuroscience
Outcome of FDA Meeting About Exanta
The Associated Press reported this evening about today's FDA meeting (see yesterday's post: Forthcoming Meeting...):
FDA Panel Urges More Studies of Stroke Med
By THE ASSOCIATED PRESS (copyright)
Filed at 8:51 p.m. ET
WILMINGTON, Del. (AP) -- A U.S. advisory panel on Friday recommended against approving AstraZeneca's new stroke prevention medication, Exanta, citing concerns about the drug's effect on the liver.
An advisory panel of physicians, meeting in Bethesda, Md., advised the Food and Drug Administration that more long-term studies are needed to assess the drug's safety, The (Wilmington) News Journal reported.
The FDA usually follows the recommendations of its advisory panels. The agency is expected to announce a decision on Exanta next month.
At the hearing, AstraZeneca made its case for Exanta's approval to the panel. Hamish Cameron, a company vice president, told the panel that Exanta represents a "real advance'' in the prevention of strokes.
But Ruyi He, an FDA official, told the panel that clinical testing of Exanta raised concerns that the drug could cause severe liver damage. He also raised concerns that patients taking Exanta may have a higher risk of heart attack.
AstraZeneca executives have portrayed Exanta as an alternative to the widely prescribed drug warfarin. Both drugs are supposed to reduce the risk of stroke by preventing blood clots.
AstraZeneca closed down 66 cents, to $43.73, on the New York Stock Exchange. The panel's recommendations were announced after the close of trading.
- Fda: Pcns Drugs Advisory Committee Results For Avid's Amyvid Alzheimer's Amyloid Neuroimaging Agent
From The New York Times: F.D.A. Sees Promise in Alzheimer’s Imaging Drug By THE ASSOCIATED PRESS Published: January 20, 2011 Filed at 5:40 p.m. ESTWASHINGTON (AP) — A federal panel of medical experts said Thursday a first-of-a-kind imaging chemical...
- Potiga (ezogabine)
From FierceBiotech FDA panel backs new epilepsy drug from GSK, Valeant August 12, 2010 — 7:41am ET By John Carroll "GlaxoSmithKline and Valeant got a solid endorsement for their new epilepsy drug Potiga (ezogabine) from the FDA's panel of experts,...
- Business World: Biogen Idec, Elan, & Tysabri (natalizumab) And Ms
From the AP, via the New York Times website: FDA Panel Supports MS Drug's Market Return By THE ASSOCIATED PRESS Published: March 8, 2006 Filed at 11:24 a.m. ET WASHINGTON (AP) -- A Food and Drug Administration panel said Wednesday the agency should...
- Methylphenidate Transdermal Patch (daytrana), Adhd, & The Fda: Thursday And Friday
THURSDAY: From The Washington Post website:Problem Found With Potential ADHD Patch The Associated Press Thursday, December 1, 2005; 3:01 PM WASHINGTON -- A patch developed to treat attention deficit hyperactivity disorder in children received a negative...
- Business World: Astrazeneca, Renovis - Cerovive (nxy-059) In Stroke Treatment
From TheStreet.com:AstraZeneca's Results Boost Tiny Renovis By Robert Steyer TheStreet.com Staff Reporter 5/4/2005 1:03 PM EDT AstraZeneca (AZN :NYSE - commentary -research ) reported mixed results for a late-stage clinical trial of an experimental...